Arnaud Beddok, Laura Rozenblum, Valentin Calugaru, Loic Feuvret, Laurence Champion, Catherine Ala Eddine, Gilles Crehange, Georges El Fakhri, Irène Buvat
{"title":"多模态成像改善患者选择和优化治疗计划和交付的病人接受再照射：范围审查。","authors":"Arnaud Beddok, Laura Rozenblum, Valentin Calugaru, Loic Feuvret, Laurence Champion, Catherine Ala Eddine, Gilles Crehange, Georges El Fakhri, Irène Buvat","doi":"10.1007/s11912-025-01708-9","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose of review: </strong>Advances in radiation therapy techniques that allow for better normal tissue sparing have made reirradiation (reRT) a more viable option for managing locoregional recurrences in various cancers. However, severe toxicity and a high risk of second recurrence persist, emphasizing the need for improved patient selection and treatment planning. This scoping review, registered in the PROSPERO database (CRD42023387364), followed PRISMA guidelines. A thorough search was conducted from 2012 to December 2023 in MEDLINE (via PubMed) and BioMed Central databases, focusing on studies that reported the value of multimodal imaging in enhancing patient selection and optimizing reRT planning. Inclusion criteria targeted studies involving MRI and PET imaging, with exclusions based on relevance, language, and quality.</p><p><strong>Recent findings: </strong>Of 363 records identified, 29 studies met inclusion criteria. Most focused on high-grade glioma (HGG, 48%), head and neck cancer (HNC, 31%), and pelvic cancer (21%). In HGG, <sup>18</sup>F-FET PET and GdT1w-MRI linked larger, metabolically active volumes with shorter overall survival (OS). Radiomic signatures from pre-reRT PET/MRI, extracted from the planned reRT volume, were associated with post-reRT recurrence, reflecting the prognostic value of intratumoral heterogeneity. Multimodal imaging differentiated disease progression from post-treatment changes, aiding target delineation. Techniques like <sup>11</sup>C-MET PET, <sup>18</sup>F-FET PET, and diffusion-weighted imaging for HGG, as well as <sup>18</sup>F-FDG PET and dynamic contrast imaging for HNC, enhanced target definition and enabled dose-painting. MRI-guided reRT reduced urinary toxicity in prostate cancer through precise treatment adaptation. Multimodal imaging is essential for patient selection, target delineation, and adaptive reRT in recurrent cancers. Further research and standardization are needed to maximize its clinical impact.</p>","PeriodicalId":10861,"journal":{"name":"Current Oncology Reports","volume":" ","pages":""},"PeriodicalIF":5.0000,"publicationDate":"2025-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Multimodal Imaging to Improve Patient Selection and Optimize Treatment Planning and Delivery for Patients Undergoing Reirradiation: A Scoping Review.\",\"authors\":\"Arnaud Beddok, Laura Rozenblum, Valentin Calugaru, Loic Feuvret, Laurence Champion, Catherine Ala Eddine, Gilles Crehange, Georges El Fakhri, Irène Buvat\",\"doi\":\"10.1007/s11912-025-01708-9\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose of review: </strong>Advances in radiation therapy techniques that allow for better normal tissue sparing have made reirradiation (reRT) a more viable option for managing locoregional recurrences in various cancers. However, severe toxicity and a high risk of second recurrence persist, emphasizing the need for improved patient selection and treatment planning. This scoping review, registered in the PROSPERO database (CRD42023387364), followed PRISMA guidelines. A thorough search was conducted from 2012 to December 2023 in MEDLINE (via PubMed) and BioMed Central databases, focusing on studies that reported the value of multimodal imaging in enhancing patient selection and optimizing reRT planning. Inclusion criteria targeted studies involving MRI and PET imaging, with exclusions based on relevance, language, and quality.</p><p><strong>Recent findings: </strong>Of 363 records identified, 29 studies met inclusion criteria. Most focused on high-grade glioma (HGG, 48%), head and neck cancer (HNC, 31%), and pelvic cancer (21%). In HGG, <sup>18</sup>F-FET PET and GdT1w-MRI linked larger, metabolically active volumes with shorter overall survival (OS). Radiomic signatures from pre-reRT PET/MRI, extracted from the planned reRT volume, were associated with post-reRT recurrence, reflecting the prognostic value of intratumoral heterogeneity. Multimodal imaging differentiated disease progression from post-treatment changes, aiding target delineation. Techniques like <sup>11</sup>C-MET PET, <sup>18</sup>F-FET PET, and diffusion-weighted imaging for HGG, as well as <sup>18</sup>F-FDG PET and dynamic contrast imaging for HNC, enhanced target definition and enabled dose-painting. MRI-guided reRT reduced urinary toxicity in prostate cancer through precise treatment adaptation. Multimodal imaging is essential for patient selection, target delineation, and adaptive reRT in recurrent cancers. Further research and standardization are needed to maximize its clinical impact.</p>\",\"PeriodicalId\":10861,\"journal\":{\"name\":\"Current Oncology Reports\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":5.0000,\"publicationDate\":\"2025-08-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current Oncology Reports\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s11912-025-01708-9\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Oncology Reports","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11912-025-01708-9","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
Multimodal Imaging to Improve Patient Selection and Optimize Treatment Planning and Delivery for Patients Undergoing Reirradiation: A Scoping Review.
Purpose of review: Advances in radiation therapy techniques that allow for better normal tissue sparing have made reirradiation (reRT) a more viable option for managing locoregional recurrences in various cancers. However, severe toxicity and a high risk of second recurrence persist, emphasizing the need for improved patient selection and treatment planning. This scoping review, registered in the PROSPERO database (CRD42023387364), followed PRISMA guidelines. A thorough search was conducted from 2012 to December 2023 in MEDLINE (via PubMed) and BioMed Central databases, focusing on studies that reported the value of multimodal imaging in enhancing patient selection and optimizing reRT planning. Inclusion criteria targeted studies involving MRI and PET imaging, with exclusions based on relevance, language, and quality.
Recent findings: Of 363 records identified, 29 studies met inclusion criteria. Most focused on high-grade glioma (HGG, 48%), head and neck cancer (HNC, 31%), and pelvic cancer (21%). In HGG, 18F-FET PET and GdT1w-MRI linked larger, metabolically active volumes with shorter overall survival (OS). Radiomic signatures from pre-reRT PET/MRI, extracted from the planned reRT volume, were associated with post-reRT recurrence, reflecting the prognostic value of intratumoral heterogeneity. Multimodal imaging differentiated disease progression from post-treatment changes, aiding target delineation. Techniques like 11C-MET PET, 18F-FET PET, and diffusion-weighted imaging for HGG, as well as 18F-FDG PET and dynamic contrast imaging for HNC, enhanced target definition and enabled dose-painting. MRI-guided reRT reduced urinary toxicity in prostate cancer through precise treatment adaptation. Multimodal imaging is essential for patient selection, target delineation, and adaptive reRT in recurrent cancers. Further research and standardization are needed to maximize its clinical impact.
期刊介绍：
This journal aims to review the most important, recently published clinical findings in the field of oncology. By providing clear, insightful, balanced contributions by international experts, the journal intends to serve all those involved in the care of those affected by cancer.
We accomplish this aim by appointing international authorities to serve as Section Editors in key subject areas, such as cancer prevention, leukemia, melanoma, neuro-oncology, and palliative medicine. Section Editors, in turn, select topics for which leading experts contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, highlighted by annotated reference lists. An international Editorial Board reviews the annual table of contents, suggests articles of special interest to their country/region, and ensures that topics are current and include emerging research. Commentaries from well-known figures in the field are also provided.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
